

Resource Summary Report

Generated by PRECISE-TBI on Jul 31, 2026

Multiple Myeloma Research Foundation

RRID:SCR_000207

Type: Tool

Proper Citation

Multiple Myeloma Research Foundation (RRID:SCR_000207)

Resource Information

URL: <http://www.themmr.org/>

Proper Citation: Multiple Myeloma Research Foundation (RRID:SCR_000207)

Description: Research foundation that funds research to develop new treatments for multiple myeloma, an incurable blood cancer.

Abbreviations: MMRF

Resource Type: institution

Keywords: drug, treatment, cancer

Related Condition: Multiple myeloma

Resource Name: Multiple Myeloma Research Foundation

Resource ID: SCR_000207

Alternate IDs: ISNI: 0000 0000 9350 5788, Crossref funder ID: 100001253, nlx_157895, Wikidata: Q6934894, grid.429426.f

Alternate URLs: <https://ror.org/03ww1bx13>

Record Creation Time: 20220129T080200+0000

Record Last Update: 20260725T190437+0000

Ratings and Alerts

No rating or validation information has been found for Multiple Myeloma Research Foundation.

No alerts have been found for Multiple Myeloma Research Foundation.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Ubels J, et al. (2018) Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects. Nature communications, 9(1), 2943.

Maura F, et al. (2018) Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia, 32(4), 1044.

Li N, et al. (2017) Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. Cell reports, 20(11), 2556.

Natoni A, et al. (2017) E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271. Leukemia, 31(12), 2642.

Miller A, et al. (2017) High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. Blood cancer journal, 7(9), e612.

Lazzari E, et al. (2017) Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nature communications, 8(1), 1922.

Vicari S, et al. (2016) Health activism and the logic of connective action. A case study of rare disease patient organisations. Information, communication and society, 19(11), 1653.

Spillane DR, et al. (2015) Chromosome Condensation 1-Like (Chc1L) Is a Novel Tumor Suppressor Involved in Development of Histiocyte-Rich Neoplasms. PloS one, 10(8), e0135755.

Grigson ER, et al. (2015) Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner. PloS one, 10(1), e0117693.